- Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
- Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer
- Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
- Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
Key statistics
On Monday, Everest Medicines Ltd (1952:HKG) closed at 16.72, 20.63% above the 52 week low of 13.86 set on Mar 15, 2022.
52-week range
Markit short selling activity
Open | 16.42 |
---|---|
High | 17.18 |
Low | 16.12 |
Bid | 16.62 |
Offer | 16.76 |
Previous close | 16.60 |
Average volume | 489.55k |
---|---|
Shares outstanding | 299.81m |
Free float | 298.17m |
P/E (TTM) | -- |
Market cap | 4.88bn HKD |
EPS (TTM) | -4.00 HKD |
Data delayed at least 15 minutes, as of Aug 08 2022 09:08 BST.
More ▼